Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...
On March 18, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the approval of the clinical trial plan by the Institutional Review Board (IRB) at Clinical Pharmacology of Miami for the company’s Phase 1 ...
Single-nucleotide polymorphisms (SNPs) associated with outcomes in patients with localized and metastatic renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from the 2017 Genitourinary ...
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade ...
New research presented at the AACE 26th Annual Congress further validates that use of Glytec’s eGlycemic Management System ® eliminates barriers to adoption of basal bolus insulin and produces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results